Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
NCT02630394Phase 1Withdrawn
- Sponsor
- University of Mississippi Medical Center
- Start
- Sep 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azithromycin in acute chest syndrome (ACS), sponsored by University of Mississippi Medical Center. Primary endpoint: Number of participants with treatment-related adverse events at 48 weeks. Planned start Sep 2015; status: withdrawn.
02
Drugs
azithromycin
03
Conditions
acute chest syndrome (ACS)
Beyond the preview
Go deeper on NCT02630394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630394.